Hyloris Developmentsen Sa
Research Hyloris Developmentsen Sa (HYL) on Bullrun: market cap EUR 126.00M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHYL
- ExchangeBR
- CountryBelgium
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 126.00M
- Financial periodFY2025
- RevenueEUR 7.21M
- Revenue growth-14.8%
- Net income-EUR 6.33M
- Free cash flow-EUR 6.99M
- Gross margin94.7%
Valuation Snapshot
latest market cap is EUR 126.00M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 7.21M | -EUR 6.33M | -EUR 6.99M | 94.7% | -0.23 | EUR 13.78M | EUR 1.61M | EUR 26.48M |
| FY2024 | EUR 8.46M | -EUR 6.34M | -EUR 7.20M | 97.3% | -0.23 | EUR 23.59M | EUR 1.82M | EUR 32.14M |
| FY2023 | EUR 2.09M | -EUR 15.38M | -EUR 13.56M | 95.5% | -0.56 | EUR 30.41M | EUR 1.75M | EUR 39.07M |
| FY2022 | EUR 900.00K | -EUR 11.91M | -EUR 13.76M | 89.6% | -0.43 | EUR 33.46M | EUR 885.00K | EUR 53.91M |
| FY2021 | EUR 3.10M | -EUR 11.58M | -EUR 12.31M | 96.5% | -0.45 | EUR 50.01M | EUR 174.00K | EUR 48.06M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 126.00M | n/a | n/a | n/a |
About Hyloris Developmentsen Sa
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Hyloris Developmentsen Sa's market cap?
Hyloris Developmentsen Sa's market capitalization is EUR 126.00M.
What does Hyloris Developmentsen Sa do?
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspension for the treatment of herpes virus infections.